Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R21/Matrix-M Malaria Vaccine in African Infants With Different Immunization Schedules
NCT06879327Phase 2Active, not recruiting
- Sponsor
- PATH
- Start
- May 2025
- Primary completion
- Oct 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of R21/Matrix-M in malaria, sponsored by PATH. Started May 2025; status: active, not recruiting.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06879327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06879327.